Role of Replication Stress during Myc-dependent Lymphomagenesis

复制应激在 Myc 依赖性淋巴瘤发生过程中的作用

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT (30 LINES) Deregulated expression of the c-Myc protooncogene is a frequent requisite for the development of many human cancers. Despite extensive knowledge of its biology, we are still unaware of the precise molecular mechanisms that sustain its oncogenic activity. Amplification of the physiologic control of DNA replication initiation by Myc upon deregulation of its expression in primary cells and transgenic mouse B-cells causes replication stress and subsequent DNA damage. Replication stress is a phenomenon often seen in early cancers from different tissue origin, and it is believed to be consequent to oncogene activation. However, formal proof for its requirement during tumorigenesis is yet to be obtained. The long-term goal of this project is to characterize the contribution of Myc-dependent replication stress to B-cell lymphomagenesis. We will specifically assess whether altering Myc's ability to promote replication stress - by either ablating its ability to control DNA replication or modifying the cellular responses to Myc- dependent replication stress- determines the outcome of the oncogenic process. We hypothesize that pathways coping with replication stress restrain tumor initiation driven by this protooncogene and hence, manipulation of these pathways will determine Myc's ability to generate lymphomas when deregulated in B-cells. This Research Plan is meant to be part of a Career Development Plan through which I aim to obtain critical knowledge and technical skills on: (1) the application of mouse models to the study cancer initiation and progression; and (2) the use of high- throughput technologies and Systems Biology to address general questions in the cancer field that, due to their complexity, require integrated approaches. The extraordinary characteristics of the host center, where all these disciplines are integrated for the study of cancer, ensure an optimal environment for the training period. The mentored phase will therefore allow me to transit with success to an independent phase, where to continue to develop the final parts of this research project, obtain proof of principle for the above proposed research hypothesis, and pursue the study of the basic mechanisms of Myc-dependent B-cell lymphomagenesis, with aim to find novel therapeutic targets for this group of diseases.
项目概要/摘要(30 行) c-Myc 原癌基因的表达失调是 许多人类癌症的发展。尽管我们对其生物学有广泛的了解,但我们仍然 仍然不知道维持其致癌活性的精确分子机制。 Myc 对 DNA 复制起始的生理控制的放大 原代细胞和转基因小鼠 B 细胞中其表达失调会导致 复制压力和随后的 DNA 损伤。复制压力是一种现象 常见于来自不同组织来源的早期癌症,并且被认为是 癌基因激活的结果。然而,其要求的正式证明 肿瘤发生机制尚未明确。该项目的长期目标是表征 Myc 依赖性复制应激对 B 细胞淋巴瘤发生的贡献。我们将 特别评估是否改变 Myc 促进复制压力的能力 - 通过 消除其控制 DNA 复制的能力或改变细胞对 Myc- 的反应 依赖性复制压力-决定致癌过程的结果。我们 假设应对复制应激的途径抑制肿瘤的发生 通过这个原癌基因,因此,操纵这些途径将决定 Myc 当 B 细胞失调时产生淋巴瘤的能力。 该研究计划是职业发展计划的一部分,通过该计划我 旨在获得以下方面的关键知识和技术技能:(1)鼠标的应用 研究癌症发生和进展的模型;和(2)使用高 通量技术和系统生物学解决癌症中的一般问题 由于其复杂性,需要综合方法的领域。非凡的 主办中心的特点,所有这些学科都整合在一起进行研究 癌症,确保训练期间的最佳环境。指导阶段 因此,我将能够成功地过渡到一个独立的阶段,在那里 继续开发该研究项目的最后部分,获得原理证明 上述提出的研究假设,并对其基本机制进行研究 Myc 依赖性 B 细胞淋巴瘤发生的研究,旨在寻找新的治疗靶点 对于这组疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Dominguez-Sola其他文献

David Dominguez-Sola的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Dominguez-Sola', 18)}}的其他基金

Decay Accelerating Factor and B cell Immunity
衰变加速因子和 B 细胞免疫
  • 批准号:
    9817322
  • 财政年份:
    2019
  • 资助金额:
    $ 24.41万
  • 项目类别:
Decay Accelerating Factor and B cell Immunity
衰变加速因子和 B 细胞免疫
  • 批准号:
    10406250
  • 财政年份:
    2019
  • 资助金额:
    $ 24.41万
  • 项目类别:
Decay Accelerating Factor and B cell Immunity
衰变加速因子和 B 细胞免疫
  • 批准号:
    10623288
  • 财政年份:
    2019
  • 资助金额:
    $ 24.41万
  • 项目类别:
Role of FOXO1 mutations in the pathogenesis of B cell non-Hodgkin lymphomas
FOXO1突变在B细胞非霍奇金淋巴瘤发病机制中的作用
  • 批准号:
    10334435
  • 财政年份:
    2018
  • 资助金额:
    $ 24.41万
  • 项目类别:
Role of FOXO1 mutations in the pathogenesis of B cell non-Hodgkin lymphomas
FOXO1突变在B细胞非霍奇金淋巴瘤发病机制中的作用
  • 批准号:
    10087895
  • 财政年份:
    2018
  • 资助金额:
    $ 24.41万
  • 项目类别:
ROLE OF REPLICATION STRESS DURING MYC-DEPENDENT LYMPHOMAGENESIS
复制应激在 MYC 依赖性淋巴细胞生成过程中的作用
  • 批准号:
    8146177
  • 财政年份:
    2010
  • 资助金额:
    $ 24.41万
  • 项目类别:
ROLE OF REPLICATION STRESS DURING MYC-DEPENDENT LYMPHOMAGENESIS
复制应激在 MYC 依赖性淋巴细胞生成过程中的作用
  • 批准号:
    7962386
  • 财政年份:
    2010
  • 资助金额:
    $ 24.41万
  • 项目类别:
Role of Replication Stress during Myc-dependent Lymphomagenesis
复制应激在 Myc 依赖性淋巴瘤发生过程中的作用
  • 批准号:
    8785173
  • 财政年份:
    2010
  • 资助金额:
    $ 24.41万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 24.41万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 24.41万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 24.41万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 24.41万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 24.41万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 24.41万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 24.41万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 24.41万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 24.41万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 24.41万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了